MEREO BIOPHARMA GROUP PLC Identifiable Assets Acquired Liabilities Assumed
MEREO BIOPHARMA GROUP PLC (MREO) had Identifiable Assets Acquired Liabilities Assumed of GBP 44.60 million as of 2019-08-23, per its 20-F filed 2022-03-31.
Discontinued › Notes
ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed · last filed 2022-03-31
- 2019-08-23: Identifiable Assets Acquired Liabilities Assumed 44.60M GBP.
- 2019-04-23: Identifiable Assets Acquired Liabilities Assumed -44.57M GBP.
| Period end | Identifiable Assets Acquired Liabilities Assumed |
|---|---|
| 2019-08-23 | 44.60M GBP 20-F · filed 2022-03-31 |
| 2019-04-23 | -44.57M GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |